International Journal of Molecular Sciences · 2021 · 27 citations · 36 references
MedicineOncologyPharmacologyApoptosisChemotherapyMolecular OncologyApoptosis In CancerApoptosis RegulationCancer Cell SignalingGastric CancerMalignant NeoplasmsOncogenic Signaling PathwaysAnticancer ActivityCancer Cell ApoptosisCancer Cell Proliferation InhibitionCancer Signaling PathwaysCell Viability AssaysPi3 Kinase-akt SignalingPi3k-akt Signaling PathwayPoly(adp-ribose) Polymerase Inhibition
Gastric cancer is the fifth most common cancer and the third leading cause of cancer-related deaths worldwide. Histone deacetylase (HDAC) inhibitors are a new class of cytostatic agents available for the treatment of various cancers and diseases. Although numerous clinical and pre-clinical trials on the anticancer effects of panobinostat have been conducted, only a few reports have investigated its efficacy in gastric cancer. The present study aimed to investigate the effects of panobinostat in gastric cancer cells. Panobinostat significantly inhibited the cell viability and proliferation of the gastric cancer cell lines SNU484 and SNU638 in a dose-dependent manner; it reduced the colony-forming ability of these cells. Moreover, it induced apoptosis as indicated by increased protein levels of cleaved poly ADP-ribose polymerase and cleaved caspase-3. Panobinostat induced the G2/M cell cycle arrest in SNU484 and SNU638 cells and subsequently decreased the G2/M phase regulatory-associated protein expression of p-Wee1, Myt1, and Cdc2. Furthermore, panobinostat significantly inhibited the metastasis of SNU484 and SNU638 cells by regulating the expression of MMP-9 and E-cadherin. Further, it decreased the protein levels of p-Akt and forkhead box protein M1 (FOXM1). These effects were reversed by the Akt agonist SC79 and were accelerated by the Akt inhibitor LY2940002. Moreover, tumor growth in xenograft animal experiments was suppressed by panobinostat. These results indicated that panobinostat inhibits the proliferation, metastasis, and cell cycle progression of gastric cancer cells by promoting apoptosis and inactivating Akt/FOXM1 signaling. Cumulatively, our present study suggests that panobinostat is a potential drug for the treatment of gastric cancer.
36
Ahmedin Jemal, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2011 · 55K citations · Full text
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
Bhupinder Mann, John R. Johnson, Martin H. Cohen et al. · The Oncologist · 2007 · 1.4K citations · Full text
Medicine, Oncology, Pharmacotherapy +14
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
Julia M. Wagner, Björn Hackanson, Michael Lübbert et al. · Clinical Epigenetics · 2010 · 396 citations · Full text